Copy to clipboard 
Medartis announced the first carpometacarpal (CMC) total joint arthroplasty in the United States using the TOUCH CMC 1 prosthesis developed and manufactured by KeriMedical and distributed by Medartis.
This follows the recent FDA approval of the device. The total joint prosthesis, used in the treatment of thumb rhizarthrosis, has established a strong market presence in EMEA over the past decade.
The prosthesis offers comprehensive clinical data support and incorporates dual mobility technology to enhance joint stability. The TOUCH prosthesis addresses a critical clinical need in hand surgery, as the CMC 1 joint is among the most commonly affected by osteoarthritis. Radiographic evidence appears in 20% to 30% of individuals over 40, with 2% to 16% progressing to symptomatic osteoarthritis that significantly impacts daily life.
“We founded KeriMedical in 2016 with the main goal of bringing the first thumb base total joint arthroplasty solution to the US market, believing that this treatment option should be the gold standard. In the time being, we became the world leading company for this joint. Bringing the TOUCH® CMC 1 dual-mobility ball-and-socket implant to the US was a challenging and exciting project for the entire company, providing robust clinical evidence and meeting FDA requirements, that mobilized massive financial and human resources over the past 5 years,” shared Bernard Prandi and Dougal Bendjaballah, KeriMedical Co-founders.
“We’re thrilled to be able to share this news after a much-anticipated wait for FDA approval of the TOUCH® CMC 1 prosthesis. This is a huge opportunity for surgeons to treat patients with a unique procedure that has already been proven successful in Europe. We have a great team that is ready to get surgeons trained on this technology and we look forward to hearing stories of patients that were able to get back to enjoying their daily lives because of this treatment option,” stated David Thoni, Medartis US President.
Source: Medartis
Medartis announced the first carpometacarpal (CMC) total joint arthroplasty in the United States using the TOUCH CMC 1 prosthesis developed and manufactured by KeriMedical and distributed by Medartis.
This follows the recent FDA approval of the device. The total joint prosthesis, used in the treatment of thumb rhizarthrosis, has...
Medartis announced the first carpometacarpal (CMC) total joint arthroplasty in the United States using the TOUCH CMC 1 prosthesis developed and manufactured by KeriMedical and distributed by Medartis.
This follows the recent FDA approval of the device. The total joint prosthesis, used in the treatment of thumb rhizarthrosis, has established a strong market presence in EMEA over the past decade.
The prosthesis offers comprehensive clinical data support and incorporates dual mobility technology to enhance joint stability. The TOUCH prosthesis addresses a critical clinical need in hand surgery, as the CMC 1 joint is among the most commonly affected by osteoarthritis. Radiographic evidence appears in 20% to 30% of individuals over 40, with 2% to 16% progressing to symptomatic osteoarthritis that significantly impacts daily life.
“We founded KeriMedical in 2016 with the main goal of bringing the first thumb base total joint arthroplasty solution to the US market, believing that this treatment option should be the gold standard. In the time being, we became the world leading company for this joint. Bringing the TOUCH® CMC 1 dual-mobility ball-and-socket implant to the US was a challenging and exciting project for the entire company, providing robust clinical evidence and meeting FDA requirements, that mobilized massive financial and human resources over the past 5 years,” shared Bernard Prandi and Dougal Bendjaballah, KeriMedical Co-founders.
“We’re thrilled to be able to share this news after a much-anticipated wait for FDA approval of the TOUCH® CMC 1 prosthesis. This is a huge opportunity for surgeons to treat patients with a unique procedure that has already been proven successful in Europe. We have a great team that is ready to get surgeons trained on this technology and we look forward to hearing stories of patients that were able to get back to enjoying their daily lives because of this treatment option,” stated David Thoni, Medartis US President.
Source: Medartis
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
